Search research articles
Contact Us
Filters
Showing results (281-290 of 302) with videos related to
Page
of 31
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
G Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
G Viale, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 24, 2015
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†
V Speirs, G Viale, K Mousa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2015
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V Bossuyt, E Provenzano, W F Symmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
L Mauriac, A Keshaviah, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
C Oakman, P A Francis, J Crown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 18, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
L Malorni, S Tyekucheva, A Gombos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2010
Quality indicators in breast cancer care
M Rosselli Del Turco, A Ponti, U Bick, et al.
Nature Communications
|
May 13, 2022
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
M G Filippone, D Gaglio, R Bonfanti, et al.
ESMO Open
|
June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06
R Shami, R Salgado, A Bardia, et al.
Page
of 31
Search research articles
Search
Showing results (281-290 of 302) with videos related to
Sort By:
Page
of 31
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
G Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
G Viale, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 24, 2015
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†
V Speirs, G Viale, K Mousa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2015
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V Bossuyt, E Provenzano, W F Symmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
L Mauriac, A Keshaviah, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
C Oakman, P A Francis, J Crown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 18, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
L Malorni, S Tyekucheva, A Gombos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2010
Quality indicators in breast cancer care
M Rosselli Del Turco, A Ponti, U Bick, et al.
Nature Communications
|
May 13, 2022
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
M G Filippone, D Gaglio, R Bonfanti, et al.
ESMO Open
|
June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06
R Shami, R Salgado, A Bardia, et al.
Page
of 31